Regeneron Pharmaceuticals and Sanofi said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in two late-stage studies.
from WSJ.com: US Business http://ift.tt/1Vfk7Ht
via IFTTT
No comments:
Post a Comment